Recent Updates
Recently added Catalysts

CD19 CAR T cells

Phase 1

Lymphomas Non-Hodgkin's B-Cell | Monoclonal antibody | Oncology |China Pharma Holdings, Inc.|Last Updated: Feb 11, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment20
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT03029338CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell LymphomaPHASE1 COMPLETED 20 — — Jun 8, 2017Jun 22, 2021Feb 11, 20261 China
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of patients with adverse events
2 years
Secondary Endpoints
Severity of the adverse events
2 years
Response rate
12 months
Progression-free survival(PFS)
2 years
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
CD19 CAR T cellsEXPERIMENTALCD19 CAR T cells will be intravenously infused to patient in a three-day split-dose regimen: 10% on day 0, 30% on day 1 and 60% on day 2.
Interventions
NameTypeDescription
CD19 CAR T cellsBIOLOGICALCD19 CAR T cells was transduced with a lentiviral vector to express anti-CD19 scFv TCRζ:4-1BB.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 70 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Patients aged 18 to 70 years with relapsed or refractory CD19 positive B-cell lymphoma. * Eastern Cooperative Oncology Group (ECOG) Performance status 0-2. * Adequate end organ function as defined by: Total bilirubin ≤ 1.5 x upper limit of normal（ULN）; Alanine aminotransferase...

Countries:China
Unlock Eligibility Criteria